SSX1 Human Pre-designed siRNA Set A contains three designed siRNAs for SSX1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

SSX2 Human Pre-designed siRNA Set A contains three designed siRNAs for SSX2 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

SSX2IP Human Pre-designed siRNA Set A contains three designed siRNAs for SSX2IP gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

SSX3 Human Pre-designed siRNA Set A contains three designed siRNAs for SSX3 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

SSX4 Human Pre-designed siRNA Set A contains three designed siRNAs for SSX4 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

SSX5 Human Pre-designed siRNA Set A contains three designed siRNAs for SSX5 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

SSX7 Human Pre-designed siRNA Set A contains three designed siRNAs for SSX7 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

st-Ht31 ammonium is a membrane-permeable peptide inhibitor of protein kinase A (PKA) anchoring. st-Ht31 ammonium induces robust cholesterol/phospholipid efflux. st-Ht31 ammonium completely reverses foam cell formation and restores the metabolic health of macrophage[1][2].

ST13 Human Pre-designed siRNA Set A contains three designed siRNAs for ST13 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

ST14 Human Pre-designed siRNA Set A contains three designed siRNAs for ST14 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

ST18 Human Pre-designed siRNA Set A contains three designed siRNAs for ST18 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

ST3 β-Gal α-2,3-Sialyltransferase 1 (ST3GAL1) is a sialyltransferase whose overexpression in ovarian cancer cell lines enhances cell growth, migration, and invasion capabilities, as well as increases tumorigenicity and resistance to paclitaxel in vivo. ST3 β-Gal α-2,3-Sialyltransferase 1 catalyzes the transfer of sialic acid from cytidine monophosphate-sialic acid to galactose-containing substrates and can be utilized in […]

ST3 β-Gal α-2,3-Sialyltransferase 1 (ST3GAL1) is a sialyltransferase whose overexpression in ovarian cancer cell lines enhances cell growth, migration, and invasion capabilities, as well as increases tumorigenicity and resistance to paclitaxel in vivo. ST3 β-Gal α-2,3-Sialyltransferase 1 catalyzes the transfer of sialic acid from cytidine monophosphate-sialic acid to galactose-containing substrates and can be utilized in […]

ST3 β-Gal α-2,3-Sialyltransferase 1 (ST3GAL1) is a sialyltransferase whose overexpression in ovarian cancer cell lines enhances cell growth, migration, and invasion capabilities, as well as increases tumorigenicity and resistance to paclitaxel in vivo. ST3 β-Gal α-2,3-Sialyltransferase 1 catalyzes the transfer of sialic acid from cytidine monophosphate-sialic acid to galactose-containing substrates and can be utilized in […]

ST3 β-Gal α-2,3-Sialyltransferase 5 (ST3GAL5) is a glycosphingolipid (GSL) biosynthetic enzyme that can inhibit TGF-β-induced epithelial-mesenchymal transition (EMT), invasion, and metastasis both in vivo and in vitro. ST3 β-Gal α-2,3-Sialyltransferase 5 can be used in cancer research[1].

ST3 β-Gal α-2,3-Sialyltransferase 5 (ST3GAL5) is a glycosphingolipid (GSL) biosynthetic enzyme that can inhibit TGF-β-induced epithelial-mesenchymal transition (EMT), invasion, and metastasis both in vivo and in vitro. ST3 β-Gal α-2,3-Sialyltransferase 5 can be used in cancer research[1].

ST3 β-Gal α-2,3-Sialyltransferase 5 (ST3GAL5) is a glycosphingolipid (GSL) biosynthetic enzyme that can inhibit TGF-β-induced epithelial-mesenchymal transition (EMT), invasion, and metastasis both in vivo and in vitro. ST3 β-Gal α-2,3-Sialyltransferase 5 can be used in cancer research[1].

ST3GAL1 Human Pre-designed siRNA Set A contains three designed siRNAs for ST3GAL1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

ST3GAL2 Human Pre-designed siRNA Set A contains three designed siRNAs for ST3GAL2 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

ST3GAL3 Human Pre-designed siRNA Set A contains three designed siRNAs for ST3GAL3 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

ST3GAL4 Human Pre-designed siRNA Set A contains three designed siRNAs for ST3GAL4 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

ST3GAL5 Human Pre-designed siRNA Set A contains three designed siRNAs for ST3GAL5 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

ST3GAL6 Human Pre-designed siRNA Set A contains three designed siRNAs for ST3GAL6 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

ST6 Sialyltransferase 5 (EC:2.4.3.3, ST6GALNAC5, SIAT7E, ST6 N-acetylgalactosaminide alpha-2,6-sialyltransferase 5) transfers a sialic acid to N-acetylgalactosamine (GalNAc) residues. ST6 Sialyltransferase 5 is a bio-marker in cervical screening samples[1][2].

ST6 Sialyltransferase 5 (EC:2.4.3.3, ST6GALNAC5, SIAT7E, ST6 N-acetylgalactosaminide alpha-2,6-sialyltransferase 5) transfers a sialic acid to N-acetylgalactosamine (GalNAc) residues. ST6 Sialyltransferase 5 is a bio-marker in cervical screening samples[1][2].

ST6 Sialyltransferase 5 (EC:2.4.3.3, ST6GALNAC5, SIAT7E, ST6 N-acetylgalactosaminide alpha-2,6-sialyltransferase 5) transfers a sialic acid to N-acetylgalactosamine (GalNAc) residues. ST6 Sialyltransferase 5 is a bio-marker in cervical screening samples[1][2].

ST6 Sialyltransferase 6 (ST6GALNAC6) belongs to the salivary transferase family, which modifies proteins and ceramides on the cell surface, thereby altering intercellular or extracellular matrix interactions. ST6 Sialyltransferase 6 can be used in the study of inflammatory bowel disease (IBD)[1][2].

ST6 Sialyltransferase 6 (ST6GALNAC6) belongs to the salivary transferase family, which modifies proteins and ceramides on the cell surface, thereby altering intercellular or extracellular matrix interactions. ST6 Sialyltransferase 6 can be used in the study of inflammatory bowel disease (IBD)[1][2].

ST6 Sialyltransferase 6 (ST6GALNAC6) belongs to the salivary transferase family, which modifies proteins and ceramides on the cell surface, thereby altering intercellular or extracellular matrix interactions. ST6 Sialyltransferase 6 can be used in the study of inflammatory bowel disease (IBD)[1][2].

ST6GAL1 Human Pre-designed siRNA Set A contains three designed siRNAs for ST6GAL1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

ST6GAL2 Human Pre-designed siRNA Set A contains three designed siRNAs for ST6GAL2 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

ST7 Human Pre-designed siRNA Set A contains three designed siRNAs for ST7 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

ST7L Human Pre-designed siRNA Set A contains three designed siRNAs for ST7L gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

ST8 alpha-2,8-Sialyltransferase 6 (ST8SIA6) is a sialyltransferase that generates α2,8-linked disialic acids, which bind to mouse Siglec-E and human Siglec-7 and -9, and accelerates tumor growth by suppressing anti-tumor immune responses[1].

ST8 alpha-2,8-Sialyltransferase 6 (ST8SIA6) is a sialyltransferase that generates α2,8-linked disialic acids, which bind to mouse Siglec-E and human Siglec-7 and -9, and accelerates tumor growth by suppressing anti-tumor immune responses[1].

ST8 alpha-2,8-Sialyltransferase 6 (ST8SIA6) is a sialyltransferase that generates α2,8-linked disialic acids, which bind to mouse Siglec-E and human Siglec-7 and -9, and accelerates tumor growth by suppressing anti-tumor immune responses[1].

ST8SIA1 Human Pre-designed siRNA Set A contains three designed siRNAs for ST8SIA1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

ST8SIA2 Human Pre-designed siRNA Set A contains three designed siRNAs for ST8SIA2 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

ST8SIA4 Human Pre-designed siRNA Set A contains three designed siRNAs for ST8SIA4 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

ST8SIA5 Human Pre-designed siRNA Set A contains three designed siRNAs for ST8SIA5 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

ST8SIA6 Human Pre-designed siRNA Set A contains three designed siRNAs for ST8SIA6 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

STAB1 Human Pre-designed siRNA Set A contains three designed siRNAs for STAB1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

STAB2 Human Pre-designed siRNA Set A contains three designed siRNAs for STAB2 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

STAC Human Pre-designed siRNA Set A contains three designed siRNAs for STAC gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

STAC2 Human Pre-designed siRNA Set A contains three designed siRNAs for STAC2 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

STAC3 Human Pre-designed siRNA Set A contains three designed siRNAs for STAC3 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

STAG1 Human Pre-designed siRNA Set A contains three designed siRNAs for STAG1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

STAG2 Human Pre-designed siRNA Set A contains three designed siRNAs for STAG2 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

STAG3 Human Pre-designed siRNA Set A contains three designed siRNAs for STAG3 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.